Free shipping starts now, no minimum, no coupons required!

CGS 19755


An NMDA Receptor Antagonist

Cat #: C-310
Alternative Name Selfotel
Lyophilized Powder yes
  • Bioassay Tested
  • Source Synthetic
    MW: 223.16
    Purity: >95%
    Form Lyophilized powder.
    Effective concentration 0.01-10 µM.
    Chemical name (2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid.
    Molecular formula C7H14NO5P.
    CAS No.: 110347-85-8
    PubChem CID 68736
    Activity CGS 19755 is a potent and competitive NMDA receptor antagonist1.
    1. Traynelis, S.F. et al. (2010) Pharmacol. Rev. 62, 405.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility 20 mM in H2O. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
    Our bioassay
    • Alomone Labs CGS 19755 inhibits NMDA (NR1+NR2A) receptors expressed in Xenopus oocytes. 
      Alomone Labs CGS 19755 inhibits NMDA (NR1+NR2A) receptors expressed in Xenopus oocytes. 
      A. Time course of NMDA currents that were elicited by stimulation with 10 µM glutamate and 10 µM glycine every 50s, while membrane potential was held at -80 mV. 0.1, 1 and 10 µM CGS 19755 (#C-310), applied for 3 min as indicated, inhibited current amplitude. B. Superimposed current traces taken from experiment described in A.
    References - Scientific background
    1. Pérez-Pinzón, M.A. and Steinberg, G.K. (1996) CNS Drug Rev. 2, 257.
    2. Bennett, D.A. et al. (1990) Prog. Clin. Biol. Res. 361, 519.
    3. Black, S.A. et al. (2014) Front. Cell. Dev. Biol2, 45.
    4. Grotta, J. et al. (1995) Stroke 26, 602.
    5. Madden, K.P. et al. (1993) Stroke 24, 1068.
    Scientific background

    CGS 19755 (Selfotel) is a highly selective, potent and competitive N-methyl-D-aspartate (NMDA) receptor antagonist. The compound binds directly to the postsynaptic NMDA receptor, competing with glutamate. CGS 19755 is a racemic mixture and a rigid analogue of 2-amino-5-phosphonopenranoic acid (AP5). The compound demonstrates anticonvulsant, anxiolytic and anti-ischemic effects. Clinically, intravenous administration of CGS 19755 is preferential over oral administration as the drug is not very active when administered orally1,2. Several studies have found that CGS 19755 has the ability to limit neuronal damage in animal stroke models.

    NMDA receptors play an important role in a variety of cellular processes and brain functions such as synaptic plasticity, addiction and stroke. They mediate physiological functions such as learning and memory formation. These receptors play a role in glutamate excitotoxicity and are involved in many neurodegenerative conditions3. NMDA antagonists are effective in limiting ischemic damage to the brain and spinal cord. As shown in several studies, this compound has the ability to prevent ischaemia-induced hippocampal cell damage in gerbils.

    These anti-ischemic properties make this compound an attractive application for clinical investigation4,5.

    Target NMDA receptors
    Last update: 06/11/2022

    CGS 19755 (#C-310) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use
    Shipping and Ordering information